Phase 2 trials focused on dose-ranging studies to identify optimal therapeutic doses
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
North Americas leadership is further strengthened by a high burden of chronic diseases that heightens interest in detoxification and immune support, as well as by growing incorporation of glutathione into beauty-from-within concepts, functional foods, and advanced skincare regimes across retail and e-commerce channels
The However, youll most likely need more exercise to help maintain weight loss after stopping semaglutide
Biochimica et Biophysica Acta
Advances in anti-obesity pharmacotherapy: current treatments, emerging therapies, and challenges